

REPRODUCTIVE HEALTHCARE

The U.S. Supreme Court decision in *Dobbs v. Jackson Women's Health* continues to have far-reaching implications for companies, healthcare providers, insurers, higher education institutions, and other organizations across the United States. Our cross-disciplinary team is comprised of regulatory, policy, investigations, and litigation lawyers, who are proactively advising clients on immediate and potential issues to address the unprecedented challenges arising in the post-Roe world.

We are recognized nationally as trusted advisors in this space, and are frequently asked to provide comments and analysis on the decision to major media organizations like *USA Today*, *Bloomberg Law* and *The Boston Globe*.

HOW WE HELP

- **Employee Benefits.** Guide employers in developing policies and procedures concerning abortion-related care and travel costs for employees
- **Privacy and Data Security.** Assist clients with post-Roe protection and disclosure of healthcare data
- **Government Investigations.** Respond to State Attorney General investigations and civil interstate subpoenas and requests for information, and assess potential criminal and civil liability
- **Regulatory Compliance.** Assess federal preemption of state laws, including with regard to ERISA, Medicare Part D, and FDA regulations
- **Government Strategies.** Provide companies, trade associations, and non-profits with government strategies advice and lobbying services regarding pending legislation in various states
- **Global Business/Human Rights.** Advise companies on corporate social responsibility implications and best practices for responding to *Dobbs*
- **Litigation.** Defend clients in reproductive healthcare-related litigation before courts and regulatory bodies across the country

SELECT REPRESENTATIVE MATTERS

- Advising a health insurance provider on potential responses and defenses to subpoenas and investigations seeking reproductive healthcare information
- Advising privately held and publicly traded companies on legal risks associated with providing travel benefits to employees located in states where abortion is illegal or restricted, including Texas and Florida
- Advising a pharmacy benefits manager on ERISA preemption issues
- Advising a Fortune 100 pharmaceutical company regarding implications arising from *Dobbs* for its women's health unit
- Advising educational institutions on reproductive healthcare-related services through student health facilities, affiliated hospitals or pharmacies, clinical programs or other course offerings
- Counseling a publicly traded pharmaceutical company regarding drug access and FDA preemption issues
- Advising a national non-profit organization regarding the legal risks arising out of the provision of reproductive healthcare and related financial assistance

WHO WE ARE


For more information contact:



Thomas Barker
202.261.7310
tbarker@foleyhoag.com



Christopher Escobedo Hart
617.832.1232
chart@foleyhoag.com



Shrutih Tewarie
212.812.0333
stewarie@foleyhoag.com